• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Survival improvement in thoracic cancer: progress from the last decade and beyond.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Manegold, C
    Thatcher, Nick
    Affiliation
    Heidelberg University, Interdisciplinary Thoracic Oncology and Department of Surgery, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. christian.manegold@chir.ma.uni-heidelberg.de
    Issue Date
    2007-08
    
    Metadata
    Show full item record
    Abstract
    Lung cancer remains a major concern, being the most common cancer worldwide, and with the incidence continuing to increase in many countries. Survival following diagnosis of non-small cell lung cancer (NSCLC) remains relatively low, with 1-year overall survival being approximately 25%. However, the development of new drugs and innovative treatment approaches is improving the outlook for patients with NSCLC. Important contributions have been made to the treatment of NSCLC and continue to do so with the development of gemcitabine, and more recently, pemetrexed. Major advances in the understanding of cancer biology have identified many potential targets for rationally designed novel therapies. Many of these targets are components of signalling pathways or metabolic processes that contribute to one of the hallmarks of the cancer phenotype. The novel targeted therapy enzastaurin, which is a derivative of the prototypical protein kinase C inhibitor staurosporine, is currently being investigated as monotherapy in NSCLC following first- or second-line chemotherapy. Research into the use of pharmacogenomics to tailor therapy to the individual patient is another innovative field that is yielding promising results that may help to improve the clinical outcome for patients with NSCLC in the future.
    Citation
    Survival improvement in thoracic cancer: progress from the last decade and beyond. 2007, 57 Suppl 2:S3-5 Lung Cancer
    Journal
    Lung Cancer
    URI
    http://hdl.handle.net/10541/108148
    DOI
    10.1016/S0169-5002(07)70420-8
    PubMed ID
    17686443
    Type
    Article
    Language
    en
    ISSN
    0169-5002
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0169-5002(07)70420-8
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Improving patient management in metastatic non-small cell lung cancer.
    • Authors: Vansteenkiste J
    • Issue date: 2007 Aug
    • Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    • Authors: Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R
    • Issue date: 2009 May 20
    • Pemetrexed for the treatment of non-small-cell lung cancer.
    • Authors: Manegold C, Schmid-Bindert G, Pilz LR
    • Issue date: 2009 Sep
    • [Stage IV NSCLC. Second-line therapy for metastatic non-small cell lung cancer].
    • Authors: Quoix E
    • Issue date: 2008 Oct
    • Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
    • Authors: Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G
    • Issue date: 2008 Mar 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.